Tradestie Institutional Equity Comparison Engine

ELVN vs ADMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ADMA Overall Edge

ADMA Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ADMA Biologics, Inc. (ADMA) driven by superior Valuation, Growth & Margin, Options & Structure while ELVN counters with relative strength in Momentum & Technical. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ADMA at 15.7x Forward P/E and 44.9% operating margin (+5.1% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against ADMA sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ADMA
ELVN N/M vs ADMA 15.7x Fwd P/E
Growth & Margin Winner ADMA
Op Margin 0.0% vs 44.9% ยท YoY +0.0% vs +5.1%
Momentum & Technical Winner ELVN
1Y +134.5% vs -12.8% ยท 52W Pos 69% vs 49%
Options & Structure Winner ADMA
CONSOLIDATION (5th %ile IV) vs SURGE (8th %ile IV)
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
1M Return +27.38%
1Y Return +134.53%
Forward P/E N/M
Unified AI Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
ADMA NASDAQ
ADMA Biologics, Inc.
Biological Products, (No Disgnostic Substances)
$13.70
+0.11% 1D
Market Cap $2.9B
1M Return +28.23%
1Y Return -12.77%
Forward P/E 15.7x
Unified AI Score
26.5 / 100 SELL
Tech 15.0 Fund 35.0 Flow 66.0 Mom 25.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELVN +134.53% ADMA -12.77% Spread: +147.3 pp (ELVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ELVN TTM Op. Margin: 0.0% ADMA TTM Op. Margin: 44.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs ADMA. Trailing 12-month operating profitability (ELVN 0.0% vs ADMA 44.9%) and valuation multiples (ELVN N/M vs ADMA 15.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELVN (4) vs ADMA (6)
Institutional Metric ELVN ADMA Criterion Row Winner
Market Capitalization Scale $3.6B $2.9B Larger Scale ELVN
Trailing P/E Ratio Valuation N/M 17.2x Lower Multiple ADMA
Forward P/E Ratio Valuation N/M 15.7x Lower Multiple ADMA
Revenue Growth (YoY) Growth +0.0% +5.1% Higher Growth ADMA
Operating Margin (TTM) Profitability 0.0% 44.9% Higher Margin ADMA
Net Profit Margin Profitability 0.0% 35.1% Higher Margin ADMA
Return on Equity (ROE) Capital Efficiency -16.8% 41.9% Higher ROE ADMA
52-Week Range Position Momentum 69% ($15โ€“$62) 49% ($7โ€“$20) Stronger Trend ELVN
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 60% Vol -0.42ฮฒ ยท 99% Vol Lower Realized Risk ELVN
Unified Institutional Score Composite Signal 35.9 / 100 (SELL) 26.5 / 100 (SELL) Higher Composite ELVN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELVN vs ADMA Buy Guide
ELVN CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live ELVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ADMA SURGE
7d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ADMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELVN nor ADMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.